Kymab Limited United Kingdom (UK)
Research
Date range: 1 December 2020 - 30 November 2021
Region: Global
Subject/journal group: All
The table to the right includes counts of all research outputs for Kymab Limited published between 1 December 2020 - 30 November 2021 which are tracked by the Nature Index.
Hover over the donut graph to view the Share for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
Count | Share |
---|---|
2 | 0.09 |
Outputs by subject (Share)
Subject | Count | Share |
---|---|---|
Life Sciences | 2 | 0.09 |
Share output for the past 5 years
2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|
0.18 | 0.32 | 0.00 | 0.31 | 0.11 |
Collaboration
Date range: 1 December 2020 - 30 November 2021
International vs. domestic collaboration by Share
- 39.96% Domestic
- 60.04% International
Hover over the graph to view the percentage of collaboration.
Top 10 domestic collaborators with Kymab Limited by Share (10 total)
-
Kymab Limited and Wellcome Trust - MRC Institute of Metabolic Science (IMS)
(0.41)
-
Kymab Limited and Cambridge University Hospitals NHS Foundation Trust
(0.23)
-
Kymab Limited and University of Cambridge
(0.19)
-
Kymab Limited and Newcastle University
(0.16)
-
Kymab Limited and UK Research and Innovation (UKRI)
(0.16)
-
Kymab Limited and South Tyneside and Sunderland NHS Foundation Trust (STSFT)
(0.09)
-
Kymab Limited and Wellcome Sanger Institute
(0.09)
-
Kymab Limited and Quadrucept Bio Ltd.
(0.04)
-
Kymab Limited and The Institute of Cancer Research (ICR)
(0.03)
-
Kymab Limited and Imperial College London (ICL)
(0.03)
Top 10 international collaborators with Kymab Limited by Share (28 total)
-
Kymab Limited and La Jolla Institute for Immunology (LJI)
(0.27)
-
Kymab Limited and Pfizer Inc.
(0.25)
-
Kymab Limited and Gulbenkian Science Institute (IGC)
(0.16)
-
Kymab Limited and Novo Nordisk A/S
(0.14)
-
Kymab Limited and Duke University
(0.10)
-
Kymab Limited and University of Lisbon (ULISBOA)
(0.09)
-
Kymab Limited and Celltrion Inc.
(0.09)
-
Kymab Limited and Generate Biomedicines, Inc.
(0.09)
-
Kymab Limited and Amsterdam UMC
(0.08)
-
Kymab Limited and Fred Hutchinson Cancer Research Center (FHCRC)
(0.06)

Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.